NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Hauser W, Petzke F, Ueyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology 2011; 50(3): 532-543. [PubMed: 21078630]
Abstract
OBJECTIVES: To evaluate and compare the efficacy and acceptability of the antidepressants amitriptyline (AMT), duloxetine (DLX) and milnacipran (MLN) for FM syndrome (FMS).
METHODS: Cochrane Library, MEDLINE, SCOPUS, www.clinicalstudyresults.org and www.clinicalTrials.gov were searched for randomized pharmacological placebo-controlled trials until 30 May 2010. Outcomes of interest were symptom reduction [pain, fatigue, sleep disturbance and reduced health-related quality of life (HRQOL)] and acceptability (total drop-out rates). We performed a meta-analysis of each drug vs placebo using a random-effects model and adjusted indirect analyses of the three drugs. Methodological quality was assessed by the Cochrane risk of bias tool.
RESULTS: Ten AMT studies (612 patients), four DLX studies (1411 patients) and five MLN studies (4129 patients) met the inclusion criteria. The reported methodological quality of most AMT trials was poor, that of DLX and MLN were high. The three drugs were superior to placebo except DLX for fatigue, MLN for sleep disturbance and AMT for HRQOL. The significant effects of AMT and DLX were small and those of MLN not substantial. In adjusted indirect comparisons, AMT was superior to DLX and MLN in reduction of pain, sleep disturbances, fatigue and limitations of HRQOL. DLX was superior to MLN in reducing pain, sleep disturbances and limitations of HRQOL. MLN was superior to DLX in reducing fatigue. There were no significant differences in acceptability of the three drugs.
CONCLUSIONS: AMT cannot be regarded as the gold standard of FMS therapy with antidepressants because of the methodological limitations of its trials.
- Review Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.[J Pain. 2010]Review Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.Häuser W, Petzke F, Sommer C. J Pain. 2010 Jun; 11(6):505-21. Epub 2010 Apr 24.
- Review Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.[Cochrane Database Syst Rev. 2013]Review Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Cochrane Database Syst Rev. 2013 Jan 31; (1):CD010292. Epub 2013 Jan 31.
- Review The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis.[CNS Drugs. 2012]Review The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis.Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. CNS Drugs. 2012 Apr 1; 26(4):297-307.
- Review Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis.[Clin Rheumatol. 2022]Review Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis.Alberti FF, Becker MW, Blatt CR, Ziegelmann PK, da Silva Dal Pizzol T, Pilger D. Clin Rheumatol. 2022 Jul; 41(7):1965-1978. Epub 2022 Mar 26.
- Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.[JAMA Netw Open. 2022]Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.Farag HM, Yunusa I, Goswami H, Sultan I, Doucette JA, Eguale T. JAMA Netw Open. 2022 May 2; 5(5):e2212939. Epub 2022 May 2.
- Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacip...Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...